- Lobbying
- alnylam AND pharmaceuticals
Lobbying Arrangements Results for 'Alnylam Pharmaceuticals'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details H.R. 5397, Joe Fiandra Access to Home Infusion Act of 2023, issues related to Medicare coverage of home infusion; issues related to the implementation of the Inflation Reduction Act; H.R. 5539/S.31... |
Alnylam Pharmaceuticals, Inc.
|
in-house lobbying | |||
Details REFUND Act; home infusion issues and April 2021 Medicare Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS). |
Alnylam Pharmaceuticals, Inc.
|
Welsh Rose, LLC | |||
Details Federal funding for Research and Development |
Fabiani & Company on behalf Alnylam Pharmaceuticals
|
Mrs. Danielle Organ Peters | |||
Details Patent reform legislation, including S. 510 Patenting of genetic sequences |
Fabiani & Company on behalf of Alnylam Pharmaceuticals
|
Mr. Martin Green | |||
Details General legislation pertaining to the improvement of the healthcare system to provide access to Medicare and Medicaid; PDUFA Reauthorization. General legislation pertaining to the improvement of th... |
Alnylam Pharmaceuticals, Inc.
|
The Conafay Group, L.L.C. | |||
Details Federal funding for research and development |
ALNYLAM PHARMACEUTICALS
|
Fabiani & Company | |||
Details Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169). |
McDermott Will & Emery LLP (obo Alnylam Pharmaceuticals)
|
Tiber Creek Group | |||
Details Advise client on legislative and administrative policy-making related to the bio-pharmaceutical industry generally, and client priorities specifically. Includes FDA and CMS related matters, as well... |
Alnylam Pharmaceuticals, Inc.
|
BGR Government Affairs | |||
Details Access to DME-infused drugs in the home, H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023 (Reps. Fitzpatrick and Dunn) Implementation of provisions included in Subtitle B of PL. 11... |
Alnylam Pharmaceuticals
|
THE MCMANUS GROUP | |||
Details Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); issues relating to Medicare Part D and Part B... |
Alnylam Pharmaceuticals, Inc.
|
Tiber Creek Group | |||
Details RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; S.476/H.R.5547, Maintaining Investments in New Innovation Act; patient access to appro... |
Alnylam Pharmaceuticals, Inc.
|
SPLITOAK STRATEGIES LLC | |||
Details Medicare coverage and reimbursement. Home Infusion. Implementation of Inflation Reduction Act of 2022. FDA regulation of platform technologies. Genetically Targeted Therapies. |
Alnylam Pharmaceuticals, Inc.
|
Todd Strategy Group |